^
1m
Phase classification • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • BGB-A445
2ms
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=35, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=100 --> 35 | Trial completion date: May 2026 --> Dec 2024 | Trial primary completion date: Jan 2026 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
docetaxel • Cyramza (ramucirumab) • BGB-15025 • BGB-A445
3ms
Enrollment change • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • BGB-A445
3ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
cisplatin • Tevimbra (tislelizumab-jsgr) • BGB-A445
6ms
Phase classification • Combination therapy • Metastases
|
Tevimbra (tislelizumab-jsgr) • BGB-A445
6ms
BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
10ms
BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=203, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Sep 2024 | Trial primary completion date: May 2025 --> Sep 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • BGB-A445
11ms
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • LBL-007
1year
Enrollment open • Combination therapy
|
docetaxel • Tevimbra (tislelizumab-jsgr) • Cyramza (ramucirumab) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445
1year
A Phase 1 (Ph1) Study of the OX40 Agonist, BGB-A445, With or Without Tislelizumab, an Anti-PD-1 Monoclonal Antibody (mAb), in Patients With Advanced Solid Tumors (COSA 2023)
BGB-A445 ± tislelizumab was well-tolerated across all doses in patients with advanced solid tumors and demonstrated preliminary antitumor activity. The dose-expansion part is ongoing in patients with NSCLC and HNSCC.
Clinical • P1 data • Metastases
|
CD4 (CD4 Molecule)
|
Tevimbra (tislelizumab-jsgr) • BGB-A445
over1year
BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=250, Recruiting, BeiGene | N=360 --> 250 | Trial completion date: Sep 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> May 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • BGB-A445
over1year
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=200, Recruiting, BeiGene | Not yet recruiting --> Recruiting | N=300 --> 200 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007
almost2years
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007